PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 12 April 1999 (12.04.99)	
International application No. PCT/AU98/00587	**Applicant's or agent's file reference** 2071058/ejh
International filing date (day/month/year) 24 July 1998 (24.07.98)	**Priority date** (day/month/year) 25 July 1997 (25.07.97)
Applicant SINGH, Mohan et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

25 February 1999 (25.02.99)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer S. Mafla
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 2071058/ejh	**FOR FURTHER ACTION**	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. **PCT/AU 98/00587**	International filing date *(day/month/year)* 24 July 1998	(Earliest) Priority Date *(day/month/year)* 25 July 1997

Applicant
(1) THE UNIVERSITY OF MELBOURNE
(2) SINGH, Mohan et al

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of **3** sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. [ ] **Certain claims were found unsearchable** (See Box I)

2. [ ] **Unity of invention is lacking** (See Box II)

3. [X] The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing

   [X] filed with the international application

   [ ] furnished by the applicant separately from the international application,

      [ ] but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed

   [ ] transcribed by this Authority

4. With regard to the **title,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**

   [X] the text is approved as submitted by the applicant

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is:

   Figure No.

   [ ] as suggested by the applicant.

   [ ] because the applicant failed to suggest a figure

   [ ] because this figure better characterises the invention

   [X] None of the figures

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 98/00587

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl[6]: C12N-15/29, 15/82 A01H-5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
WPAT, CA

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
MEDLINE, DNA DATABASES (GENBANK, EMBL, SWISSPROT, PIR) see below

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
DNA DATABASES: SEQ ID Nos 4, 6, 8, 9 WPAT: [(C12N-015/29/IC OR A01H/IC) OR C12N-015/11/IC) AND (GENERATIVE OR GAMET: OR SPERM#)] OR (C12N-015/11/IC AND POLLEN:) MEDLINE: POLLEN/CT AND (GAMET? OR GERM? OR GENERATIVE OR SPERM?)
CA: POLLEN/CT AND [GENERATIVE OR SPERM OR (MALE GAMET?) OR (MALE(5N)GERMLINE)]

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	The Plant Journal 13(6), pages 823-829 (1998) Xu, Huiling et al "Plant homologue of human excision repair gene ERCCI points to conservation of DNA repair mechanism".	1-3
X	Plant Mol. Biol. 31 pages 1083-6 (1996) Blomstedt, C.K. et al "Generative cells of Lilium longiflorum possess translatable mRNA and functional protein synthesis machinery" See page 1084 column 1, line 14-completion of article	1-3

[X] Further documents are listed in the continuation of Box C

[ ] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
	28 AUG 1998
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929	Authorized officer **JIM CHAN** Telephone No.: (02) 6283 2340

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 98/00587

C (Continuation) **DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Developmental Biology 169, pages 210-17 (1995) Ueda, K and Tanaka, I. "The Appearance of Male gamete-specific histones gH2B and gH3 during pollen development in Lilium longiflorum" See results and discussion	1-8
X	Planta 197, pages 289-92 (1995) Ueda, K. and Tanaka, I. "Male gametic nucleus-specific H2B and H3 histones designated gH2B and gH3, in Lilium longiflorum" See discussion	1-8
A	"Molecular and Cellular Aspects of Plant Reproduction", pages 83-135 (1994) Cambridge University Press. Scott, R.J. and Stead, A.D. eds. "The diversity and regulation of gene expression in the pathway of male gametophyte development" See in particular pages 106-107	1-10

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2071058/EJH/AF	**FOR FURTHER ACTION**	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International application No. **PCT/AU 98/00587**	International filing date *(day/month/year)* 24 July 1998	Priority Date *(day/month/year)* 25 July 1997
International Patent Classification (IPC) or national classification and IPC **Int. Cl.**[6] C12N 15/29, 15/82 A01H 5/00		
Applicant THE UNIVERSITY OF MELBOURNE et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

[X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of **3** sheet(s).

3. This report contains indications relating to the following items:

- I [X] Basis of the report
- II [ ] Priority
- III [ ] Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV [ ] Lack of unity of invention
- V [X] Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI [ ] Certain documents cited
- VII [ ] Certain defects in the international application
- VIII [ ] Certain observations on the international application

Date of submission of the demand 25 February 1999	Date of completion of the report 3 November 1999
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. (02) 6285 3929	Authorized Officer **TERRY MOORE** Telephone No. (02) 6283 2569

International application No.
PCT/AU 98/00587

I. Basis of the report

1. With regard to the **elements** of the international application:*

☐ the international application as originally filed.

☒ the description, pages **1-35,** as originally filed,
pages , filed with the demand,
pages , filed with the letter of .

☒ the claims, pages , as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages **36-38,** filed with the letter of **17 May 1999 and 15 July 1999.**

☒ the drawings, pages **1/12-12/12,** as originally filed,
pages , filed with the demand,
pages , filed with the letter of .

☐ the sequence listing part of the description:
pages **27-35,** as originally filed
pages , filed with the demand
pages , filed with the letter of .

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, was on the basis of the sequence listing:

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report*

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	**1-20**	**YES**
	Claims		**NO**
Inventive step (IS)	Claims	**4, 5 and 7-20**	**YES**
	Claims	**1-3 and 6**	**NO**
Industrial applicability (IA)	Claims	**1-20**	**YES**
	Claims		**NO**

2. Citations and explanations (Rule 70.7)

Documents considered in providing this report:

D1 Blomstedt, C.K. et al (1996) Plant Mol. Biol. 31, 1083-6
D2 Ueda, K. et al (1995) Developmental Biology 169, 210-17
D3 Ueda, K. et al (1995) Planta 197, 289-92

Xu et al (1998) The Plant J. 13(6), 823-9 is not discussed. This document was published later than the earliest priority date for the present application and therefore is not relevant unless the priority date of the present application is challenged.
"Molecular and Cellular Aspects of Plant Reproduction" is also not discussed in this report as it discloses background information that does not impinge on the novelty or inventive merit of the claims.

The instant specification discloses nucleic acid sequences corresponding to the coding regions and regulatory sequences of three lily generative and sperm cell specific transcripts.

D1 discloses isolation of lily generative cells. The generative cells were then used in translation assays to identify proteins translated from mRNAs specific to generative cells. The translations yielded 10 proteins, 6 of which were unique to generative cells. The analysed proteins possessed a range of pI values indicating that they represent a range of proteins, potentially both histone and non-histone. As such the citation discloses the presence of nucleic acid molecules specific to generative cells and provides the peptide products of their translation.

The examiner accepts the attorney's argument that the citation does not disclose isolated nucleic acid molecules representative of generative-cell specific mRNAs. However the citation does disclose the presence of nucleic acid molecules representative of a general pool of generative-cell specific mRNAs. Therefore it appears that the citation clearly demonstrates that there are generative-cell specific transcripts and that they are present in sufficient quantities to provide detectable translation products from *in vitro* translation assays (see figure 2 of the citation). This discovery is clearly stated in the final paragraph of the citation, where the authors encourage further analysis of the mRNAs and their peptide products.

Continued in supplemental box.

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of : Box V2

As such the citation provides a clear signpost providing the PSA with both encouragement and the expectation of success in attempts to isolate mRNA species representative of generative-cell specific gene products. Given this signpost it would be obvious to the PSA to use standard techniques such as subtracted cDNA probes or differential screening to isolate transcripts representative of the pool of generative-cell specific mRNAs disclosed in the citation. These techniques and their application to the isolation of cell and stage specific RNA species are comprehensively discussed in such standard laboratory texts as Sambrook et al "Molecular Cloning: A Laboratory Manual" and appear similar to the differential hybridisation of cDNA clones disclosed in the specification

Therefore, in summary the examiner submits that the citation provides proof that generative cells possess their own pool of translatable, cell-specific mRNAs, both histone and non-histone, and provides incentive for the standard isolation of generative-cell specific mRNAs. Although the prior art has not disclosed the identity of specific generative cell mRNA transcripts, for example SEQ ID NOS 3, 5, 7, and 9, the document readily predicts the presence of a generative-specific RNA pool and promotes isolation of representatives of this pool. As a result claims 1-3 and 6, which disclose any unspecified generative-cell specific nucleic acid molecule, appear to lack inventive merit.

D2 and D3 disclose lily histone variants H2B and H3, shown to be specifically expressed in generative and sperm cells. The citations disclose the isolation of these histone proteins and analysis of their amino acid compositions. As such the citations identify what appear to be histone peptides that share homology with the applicant's sequences disclosed in SEQ ID Nos 5-8. However the applicant has specifically excluded histone sequences from the scope of the claims 1-8, 11-13, 16 and 18-20 and therefore has distinguished the claimed sequences from those taught by the citations. As such claims 1-8, 11-13, 16 and 18-20 appear to be both novel and inventive when compared to D2 and D3. In addition neither of the citations disclose the non histone-related sequences defined in claims 9, 10, 15 and 17 or the specific sequences defined in claim 14 and therefore these claims appear to define subject matter that is both novel and inventive in light of either of D2 or D3.

The claims discloses sequences, methods and plants appropriate for use in the generation of useful transgenic plants and genetic constructs. Therefore the subject matter of the claims is industrially applicable.

Received 17 May 2000

CLAIMS:

1. (Amended)An isolated nucleic acid molecule comprising a nucleotide sequence or a complementary nucleotide sequence corresponding to a gene or derivative thereof or a region of said gene facilitating its expression wherein said gene is specifically expressed in generative cells and sperm cells of a plant but wherein said gene does not encode a histone.

2. An isolated nucleic acid molecule according to claim 1 wherein said plant is selected from a legume, crop plant, cereal plant, a grass, a fruiting plant and a flowering plant.

3. An isolated nucleic acid molecule according to claim 2 wherein the plant is a lily or a related plant.

4. An isolated nucleic acid molecule according to claim 3 comprising a nucleotide sequence which encodes an amino acid sequence selected from SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 or an amino acid sequence having at least 40% identity to any one of SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

5. An isolated nucleic acid molecule according to claim 4 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 or a nucleotide sequence having at least 50% identity to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 or is a nucleotide sequence capable of hybridizing to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 under low stringency conditions at 42°C.

6. An isolated nucleic acid molecule according to claim 1 or 3 wherein said nucleic acid molecule is a promoter or a functional derivative which directs plant generative cell and sperm cell specific expression.

7. An isolated nucleic acid molecule according to claim 6 comprising a nucleotide sequence or complementary nucleotide sequence which is capable of hybridizing under low stringency conditions at 42°C to a genomic region encompassing at least about 2 kbp upstream of the

genomic nucleotide sequence corresponding to any one of SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:7.

8. An isolated nucleic acid molecule according to claim 6 comprising a nucleotide sequence or complementary nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9.

9. An isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9 and wherein said nucleic acid molecule is capable of directing plant generative cell and sperm cell specific expression of a nucleotide sequence operably linked thereto.

10. An isolated nucleic acid molecule according to claim 9 wherein the nucleotide sequence operably linked to the nucleic acid molecule encodes or defines GUS, GFP, a ribonuclease, DTA, an antisense molecule, a transposon or a lethal gene.

11. (Amended)A method of inducing or otherwise facilitating male sterility in a plant, said method comprising operably linking a cytotoxic nucleic acid molecule to a promoter which directs plant generative cell and sperm cell specific expression in said plant such that upon direction by said promoter, the cytotoxic nucleic acid molecule is expressed to produce a product which inactivates, kills or otherwise renders substantially non-functional generative cells and/or sperm cells in said plant wherein said promoter is not a histone gene-specific promoter.

12. A method according to claim 11 wherein said plant is a legume, crop plant, cereal plant, a grass, a fruiting plant and a flowering plant.

13. A method according to claim 11 wherein the cytotoxic nucleic acid molecule encodes or comprise a cytotoxic protein, an antisense molecule to a particular gene, a ribozyme or a plantabody.

14. A method according to claim 11 wherein the promoter corresponds to a nucleotide sequence which hybridizes under low stringency conditions to a genomic region comprising at least about 2kbp upstream of a gene corresponding to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7.

15. A method according to claim 14 wherein the promoter comprises a nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9.

16. (Amended) A genetic construct comprising a generative cell and sperm cell specific promoter operably linked to a transposase gene, said transposase gene capable of inducing transposition of a transposable element such that upon expression of said promoter, the transposase gene is expressed facilitating transposition of said transposable element wherein said promoter is not a histone gene-specific promoter.

17. A genetic construct according to claim 16 wherein where the promoter comprises a nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9.

18. A genetic construct according to claim 16 or 17 wherein the transposase gene is the activator (Ac) transposase.

19. A male sterile plant generated by the method of any one of claims 11 to 15.

20. A male sterile plant according to claim 19 which provides seedless fruit or fruit with reduced seed content.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

HUGHES, E., John, L.
Davies Collison Cave
1 Little Collins Street
Melbourne, VIC 3000
AUSTRALIE

Date of mailing (day/month/year)
27 January 1999 (27.01.99)

Applicant's or agent's file reference
2071058/ejh

IMPORTANT NOTIFICATION

International application No.
PCT/AU98/00587

International filing date (day/month/year)
24 July 1998 (24.07.98)

1. The following indications appeared on record concerning:

[X] the applicant [X] the inventor [ ] the agent [ ] the common representative

Name and Address	State of Nationality	State of Residence
	IN	AU
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[X] the person [X] the name [X] the address [ ] the nationality [ ] the residence

Name and Address	State of Nationality	State of Residence
SINGH, Manjit 1/30 Park Drive Parkville, VIC 3052 Australia	IN	AU
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:
New applicant/inventor for the US only.

4. A copy of this notification has been sent to:

[X] the receiving Office
[ ] the International Searching Authority
[ ] the International Preliminary Examining Authority
[ ] the designated Offices concerned
[ ] the elected Offices concerned
[ ] other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer
Facsimile No.: (41-22) 740.14.35	Athina Nickitas-Etienne Telephone No.: (41-22) 338.83.38

Form PCT/IB/306 (March 1994)

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/29, 15/82, A01H 5/00

A1

(11) International Publication Number: **WO 99/05281**

(43) International Publication Date: 4 February 1999 (04.02.99)

(21) International Application Number: PCT/AU98/00587

(22) International Filing Date: 24 July 1998 (24.07.98)

(30) Priority Data:

PO 8233	25 July 1997 (25.07.97)	AU
PP 1184	31 December 1997 (31.12.97)	AU

(71) Applicant *(for all designated States except US)*: THE UNIVERSITY OF MELBOURNE [AU/AU]; Grattan Street, Parkville, VIC 3052 (AU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SINGH, Mohan [AU/AU]; 7 Lloyd Court, Templestowe, VIC 3106 (AU). BHALLA, Prem [AU/AU]; 7 Lloyd Court, Templestowe, VIC 3106 (AU). XU, Hui-Ling [AU/AU]; 19 Roseland Grove, Doncaster, VIC 3108 (AU). SWOBODA, Ines [AT/AU]; 2/234 Cardigan Street, Carlton, VIC 3053 (AU).

(74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: NOVEL NUCLEIC ACID MOLECULES AND USES THEREFOR

(57) Abstract

The present invention relates generally to a novel nucleic acid molecule. More particularly, the present invention relates to a male germ line cell specific genetic sequence in plants. Male germ line cells include generative cells and sperm cells. Even more particularly, the present invention provides a male germ line specific gene or functional equivalent thereof and to the promoter of said gene or its functional derivatives and their use in generating a range of mutant plants including male sterile plants and transposon tagged plants.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

NOVEL NUCLEIC ACID MOLECULES AND USES THEREFOR

FIELD OF THE INVENTION

The present invention relates generally to a novel nucleic acid molecule. More particularly, the present invention relates to a male germ line cell specific genetic sequence in plants. Male germ line cells include generative cells and sperm cells. Even more particularly, the present invention provides a male germ line specific gene or functional equivalent thereof and to the promoter of said gene or its functional derivatives and there use in generating a range of mutant plants including male sterile plants and transposon tagged plants.

BACKGROUND OF THE INVENTION

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description.

The increasing sophistication of recombinant DNA technology is greatly facilitating research and development in a range of industries and is particularly beneficial for the agricultural and horticultural industries. The ability to manipulate plants and plant products by recombinant means offers great potential to generate relatively quickly new varieties of plants, plants with beneficial genetic alterations and modified plant products, such as grains and fruits.

One important area of the plant industry is the production of hybrid plants. The production of hybrid plants from essentially homozygous parents permits the introduction of a range of beneficial traits including disease resistance, higher seed yield, frost resistance and altered nutritional characteristics.

Due to the importance of hybrid plants to the agricultural and horticultural industries in general, much research has been undertaken to finding improved, more efficacious ways of producing heterozygotic plants. The production of hybrid plants requires that a female parent does not self-fertilize. A range of physical, chemical and genetic techniques have been used or have been

proposed in order to prevent self-fertilization. Although some of these techniques have been partially successful, there is still a need to develop alternative, more broadly applicable methods of preventing self-fertilization.

Another important area of the agricultural and horticultural industries is the generation of mutants. Mutant plants may in themselves be useful in removing unwanted traits or may be useful as recipients for further genetic manipulation such as the introduction of new genetic material. Mutant plants have been obtained by a range of procedures including chemical and genetic manipulation as well as physical manipulation and classical breeding. One particularly useful mutant generating mechanism is "transposon tagging".

Transposons are distinct genetic elements capable of inserting into different sites of the genome within the same cell. Two broad categories of transposons are known comprising the DNA based transposon which transpose *via* DNA intermediates and retrotransposons or retroelements, which transpose *via* RNA intermediates. Transposons are useful tools for transposon tagging which relies upon a recognizable phenotype being caused by the insertion into a gene of a transposon. Transposon tagging has found particular application in the cloning of genes.

One system of transposon tagging uses the *Activator/Dissociation* (*Ac/Ds*) elements from maize (1). This system comprises a *trans*-activator, Ac^{st}, which provides a transposase and a *cis*-responsive *Ds* element. The transposase promotes high frequency germinal excision of *Ds* which then reintegrates frequently into new genomic sites after excision.

However, despite the need for male sterile plants and the availability of mutagenic techniques such as transposon tagging, progress has been hampered by the inability to target germ line cells. In work leading up to the present invention, the inventors have identified cDNA clones exhibiting strict generative cell specific expression.

The development of male gametes is one of the most important events in the life cycle of flowering plants. The generative cell, the progenitor of male gametes, plays a central role in this process. This role is to produce two male gametes, the sperm cells, which participate in

fertilization. The generative cell residues within the cytoplasm of another cell, the vegetative cell and, until now, was thought to be transcriptionally inactive.

In work leading up to the present invention, the inventors have identified genes which are male gamete specific. The genes and their corresponding promoters of the present invention will enable specific genetic manipulation of the male germ line including generating male sterile plants and facilitating male gamete specific transposon tagging.

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.

One aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence or a complementary sequence corresponding to a gene or derivative thereof or a region of said gene facilitating its expression wherein said gene is specifically expressed in a male gamete of a plant.

Another aspect of the present invention is directed to a nucleic molecule comprising a nucleotide sequence or complementary sequence encoding an amino acid sequence selected from SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 or an amino acid sequence having at least 40% similarity to any one of SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 wherein said nucleic acid molecule exhibits male gamete specific expression in plants.

Another aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence selected from the group consisting

of SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 or a nucleotide sequence having at least 50% similarity to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 or is a nucleotide sequence capable of hybridizing to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 under low stringency conditions at 42°C.

Still yet another aspect of the present invention provides a nucleic acid molecule comprising a promoter or functional derivative thereof which directs plant male gamete specific expression in a nucleotide sequence operably linked thereto.

Even still another aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence which is capable of hybridizing under low stringency conditions at 42°C to a genomic region encompassing at least about 2kbp upstream of the nucleotide sequence corresponding to any one of SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:7 and wherein said nucleic acid molecule is capable of directing plant male gamete specific expression of a nucleotide sequence operably linked thereto.

Another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% similarity to SEQ ID NO:9 and wherein said molecule is capable of directing plant male gamete specific expression of a nucleotide sequence operably linked thereto.

A further aspect of the present invention contemplates a method of inducing or otherwise facilitating male sterility in a plant, said method comprising operably linking a cytotoxic nucleic acid molecule to a promoter which directs male gamete specific expression in said plant such that upon expression of said promoter, the cytotoxic nucleic acid molecule is expressed to produce a product which inactivates, kills or otherwise renders substantially non-functional male gametes in said plant.

Another aspect of the present invention provides a genetic construct comprising a male gamete

specific promoter, as hereinbefore described, operably linked to a transposase gene, said transposase gene capable of inducing transposition of a transposable element, such that upon expression of said promoter, the transposase gene is expressed facilitating transposition of said transposable element.

Reference herein to "male gamete" includes reference to generative cells and sperm cells.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a representation of the nucleotide [SEQ ID NO:3] and predicted amino acid [SEQ ID NO:4] sequence of *LGC1*.

Figure 2 is a photographic representation showing expression of *LGC1* mRNA in different tissues of lily. (**A**) Northern blot of the indicated tissues probed with ^{32}P-labelled *LGC1* probe. GCs, generative cells. (**B**) RT-PCR of different tissues. Pollen mRNA includes contribution of both generative cell and vegetative cell. Numbers 16, 31, 64 represent 1/16, 1/32, and 1/64 of the mRNA input respectively and so forth. Molecular sizes are indicated on the left.

Figure 3 is a photographic representation showing in situ hybridization of *LGC1* mRNA to whole mount lily pollen. Dark staining in the generative cell (arrowhead) represents hybridization signals detected by an alkaline phosphatase conjugated anti-DIG antibody. The outer wall of pollen, exine appears as a sculptured pattern. (**A**) Pollen probed with a DIG-UTP labelled *LGC1* antisense riboprobe. (**B**) Control pollen probed with a sense riboprobe.

Figure 4 is a photographic representation showing *in situ* hybridization of *LGC1* mRNA to whole mount lily pollen at different developmental stages. For a better resolution, protoplasts of developing pollen were released from sculptured exine, the outer wall of pollen (9). Developing pollen (**A-E**) and pollen tube (**K**) probed with a DIG-UTP labelled riboprobe and then counter-stained with 4′, 6′-diamidino-2-phenyl indole (DAPI) to visualize the vegetative and generative nuclei within pollen (**F-J**) and sperm nuclei in pollen tube (**L**). Arrowheads indicate the generative cell at early developmental stages. GN, generative nucleus; VN,

vegetative nucleus; SC, sperm cell; SN, sperm nucleus.

Figure 5 is a representation showing nucleotide [SEQ ID NO:5] and deduced amino acid [SEQ ID NO:6] sequences of the *gcH2A* cDNA. The predicted amino acid sequence (numbered at right) is given below the corresponding nucleic acid sequence (numbered at left).

Figure 6 is a representation showing nucleotide [SEQ ID NO:7] and deduced amino acid [SEQ ID NO:8] sequences of the Full Length *gcH3* cDNA. Numbers at left indicate base positions of the nucleotide sequence, numbers at right residue positions of the derived amino acid sequence.

Figure 7 is a photographic representation showing expression pattern of gcH2A and gcH3.

Figure 8 is a photographic representation showing *in situ* hybridization of gcH2A and gcH3 in pollen. Pollen exine was removed for a better visualising of signal.

(A) Pollen probed with showing strong hybridization signal in the generative cell.

(B) Control pollen probed with DIG-labelled sense gcH2A.

(C) Pollen probed showing strong hybridization signal in the generative cell.

(D) Control pollen probed with DIG-labelled sense gcH3.

Figure 9 is a photographic representation showing expression of gcH2A and gcH3 during pollen development. *In situ* hybridization of microspores immediately after formation of generative cell (A, D, G), nearly mature pollen (B, E, H) and mature pollen (C, F, I). Arrow heads indicate nearly formed generative cell, VN, vegetative nucleus, GN, generative cell nucleus. Pollen exine was removed for a better visualising of signal.

(A), (B), (C) samples probed with DIG-labelled antisense gcH2A showing strong hybridization signal only in mature pollen.

(G), (H), (I) samples probed with DIG-labelled antisense gcH3 showing hybridization signal only in mature pollen.

(D), (E), (F) DAPI staining of corresponding developmental stages.

Figure 10 is a representation of the nucleotide sequence of the LGC1 promoter. The

transcription start site (nucleotide position 817) and the translation start site (nucleotide position 894) are shown bold and are underlined.

Figure 11 is a diagrammatic representation showing various constructs comprising the LGC1 promoter, a DNA sequence operably linked thereto and a selectable marker gene (reporter genetic sequence).

Figure 12(A) is a diagrammatic representation of a genetic construct comprising the *LGC1* promoter operably linked to a *Gus* reporter gene. The genetic construct further comprises a gene conferring a selectable marker.

Figure 12(B) is a photographic representation showing *Gus* gene expression using the genetic construct of Figure 12(A) in mature pollen counterstained with 4', 6'-diamindino-2-phenylindole (DAPI). The observed activity of the *LGC1* 5'-flanking region thus reflects expression of endogenous *LGC1* in lily pollen.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence or a complementary sequence corresponding to a gene or derivative thereof or a region of said gene facilitating its expression wherein said gene is specifically expressed in a male gamete of a plant. A male gamete is considered to include a vegetative cell and a sperm cell.

The nucleic acid molecule of the present invention extends to a genomic or cDNA molecule corresponding to a gene or its derivative or a promoter of said gene or a functional derivative of said promoter, provided the promoter permits male gamete specific expression of the gene or its derivative.

The plant may be a monocotyledonous or dicotyledonous plant. Preferred plants include but are not limited to legumes, crop, cereal and native grasses, fruiting plants, flowering plants amongst many others. One particularly preferred plant is a lily plant.

In another embodiment, the present invention is directed to a nucleic molecule comprising a nucleotide sequence or complementary sequence encoding an amino acid sequence selected from SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 or an amino acid sequence having at least 40% similarity to any one of SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 wherein said nucleic acid molecule exhibits male gamete specific expression in plants. The preferred gene of this aspect of the present invention is referred to as the *"LGC1"* gene.

Preferably, the percentage similarity is at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, yet even more preferably at least about 80-90% or greater to any one of SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

Another aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 or a nucleotide sequence having at least 50% similarity to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 or is a nucleotide

sequence capable of hybridizing to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 under low stringency conditions at 42°C.

Preferably, the percentage level of nucleotide similarity is at least about 60%, more preferably at least about 70%, still more preferably at least about 80%, yet still more preferably at least about 90% or greater to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7.

Reference herein to a low stringency at 42°C includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions. In general, washing is carried out $T_m = 69.3 + 0.41$ (G+C)% [19]. However, the T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatch base pairs (20).

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels.

Preferably, comparisons of nucleotide and amino acid sequences are in terms of percentage identity and this includes the number of exact nucleotide or amino acid matches having regard to an appropriate alignment using a standard algorithm, such as but not limited to the Geneworks

programme (Intelligenetics).

Reference to a "derivative" herein includes single or multiple nucleotide or amino acid substitutions, deletions and/or additions as well as parts, fragments, portions, homologues and analogues of the nucleotide or amino acid sequence.

The nucleic acid molecules of the present invention are specifically expressed in male gametes of plants, ie. in the generative cells. The male gamete specific expression is determined in part by the male gamete specific promoter.

Accordingly, another aspect of the present invention provides a nucleic acid molecule comprising a promoter or functional derivative thereof which directs plant male gamete specific expression in a nucleotide sequence operably linked thereto.

More particularly, this aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence which is capable of hybridizing under low stringency conditions at 42°C to a genomic region encompassing at least about 2kbp upstream of the nucleotide sequence corresponding to any one of SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:7 and wherein said nucleic acid molecule is capable of directing plant male gamete specific expression of a nucleotide sequence operably linked thereto.

Even more particularly, this aspect of the present invention is directed to an isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% similarity to SEQ ID NO:9 and wherein said molecule is capable of directing plant male gamete specific expression of a nucleotide sequence operably linked thereto.

The nucleotide sequence of SEQ ID NO:9 represents the promoter of the LGC1 gene and is referred to herein as the LGC1 promoter. The present invention encompasses the LGC1 promoter comprising a nucleotide sequence substantially as set forth in SEQ ID NO:9 or any

derivative thereof which includes mutants, fragments, homologues and analogues thereof. Such derivatives are conveniently further defined by being able to hybridize under low stringency conditions at 42°C to SEQ ID NO:9 and/or have a nucleotide sequence of about 50% similarity to SEQ ID NO:9. Generally, the derivatives retain at least partial promoter activity and, hence, are "functional" derivatives. However, non-functional derivatives are also encompassed by the present invention since these have utility, for example, in inhibiting promoter activity and as probes for other similar promoters.

In SEQ ID NO:9, the transcription start site is at nucleotide position 817 and the translation start site (ATG) is at nucleotide position 894.

The present invention further extends to a variety of genetic constructs comprising the LGC1 promoter or its derivatives together with a nucleotide sequence operably linked to the promoter and optionally a report molecule. Examples of nucleotide sequences operably linked to the promoter include, but are not limited to, those encoding GUS, GFP, ribonuclease, DTA, antisense molecules, transposons, ribozymes and lethal genes amongst many others.

The identification of a male gamete specific promoter and gene permits the generation of a range of male sterile plants as well as male gamete specific transposon tagging.

In one embodiment, the present invention contemplates a method of inducing or otherwise facilitating male sterility in a plant, said method comprising operably linking a cytotoxic nucleic acid molecule to a promoter which directs male gamete specific expression in said plant such that upon expression of said promoter, the cytotoxic nucleic acid molecule is expressed to produce a product which inactivates, kills or otherwise renders substantially non-functional male gametes in said plant.

The cytotoxic nucleic acid molecule may encode or comprise a cytotoxic protein, an antisense molecule to a particular gene, a ribozyme or a plantabody amongst many other molecules.

Preferably, the promoter corresponds to a nucleotide sequence which hybridizes under low

stringency conditions to a genomic region comprising at least about 2kbp upstream of a gene corresponding to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7. More particularly, the promoter is the LGC1 promoter or its derivatives.

Alternatively, the cytotoxic nucleic acid molecule is fused to the gene naturally operably linked to said promoter such that upon expression of said gene, the cytotoxic nucleic acid molecule inactivates, kills or otherwise renders substantially non-function a male gamete in said plant.

In another embodiment, the male gamete specific promoter and/or gene is used to facilitate male gamete specific transposon tagging. This facilitates the product of pollen grains in a plant carrying a transponson tag. Offspring can then be screened for a range of phenotypes of interest and then, in turn, the transponson tagged plants used to clone particular genes.

Accordingly, another aspect of the present invention provides a genetic construct comprising a male gamete specific promoter, as hereinbefore described, operably linked to a transposase gene, said transposase gene capable of inducing transposition of a transposable element, such that upon expression of said promoter, the transposase gene is expressed facilitating transposition of said transposable element.

A particularly useful transposon system is the Ds^{ALS} system (1, 5) where the activator (Ac) transposase would be under the control of the promoter of the present invention to facilitate transposition of the dissociation (Ds) element.

In accordance with the present invention a plant is selected such as a crop plant, legume, grass plant or flowering plant amongst other monocots and dicots and a callus culture prepared. A genetic construct comprising the male gamete specific promoter and optionally male gene specific gene naturally associated with said promoter operably linked to a cytotoxis nucleic acid molecule or a transposase gene is introduced into callus cells. A plant is then regenerated. The male gamete specific construct may be under additional control mechanisms such as environmental, developmental, physiological or nutritional control mechanisms such that upon provision of these mechanisms, the male gamete specific promoter is activated. In any event,

upon expression of the male gamete specific promoter, transposon tagging will occur or the cytotoxic nucleic acid will be expressed. This will result in tagged pollen or male sterility.

Male sterile plants containing a range of transposon insertions and genetic constructs useful of the practice of the present invention are all encompassed by the present invention as are all offspring or progeny, new plant varieties and mutant plants.

The present invention extends to the promoter as herein described as well as functional mutants thereof. A functional mutant includes promoter fusions to other promoters, as well as single or multiple nucleotides, deletions, additions and/or substitutions including parts, fragments, portions, homologues and analogues thereof.

Although not intending to limit the present invention to any one type of male gamete specific gene or promoter, genes and their promoters encoding histones are particularly useful.

Another benefit of the present invention provides the potential to develop seedless fruit or fruit with reduced seed content. This is particularly applicable where pollination stimulates fruit development and where the lack of fertilization results in seedless fruit.

The present invention extends to any transposable element such as but not limited to *Ac, Ds, En/Spm, dspm,* Tam3, dTam3, Mu1, Tat1, Tag1, dTph1, Tnt1, Tto1, Tto2, Ac-like, dTnp and Tos17. These elements are conveniently reviewed in the reference (16).

The present invention is further described by the following non-limiting Examples.

EXAMPLE 1
ISOLATION OF *LGC1*

Generative cells from lily *(Lilium longiflorum)* were isolated and mRNA isolated therefrom. Generative cells were isolated from fresh pollen of lily as previously described (6) and stored at -70°C until use. mRNA was extracted directly from approximately 1 x 10^5 of stored generative cells using a mRNA purification kit (Pharmacia-LKB). Purified generative cell mRNA was reverse transcribed and the resultant cDNA was amplified by PCR, size fractionated and cloned into λgt11 expression vector.

A differential hybridization approach was used to obtain a cDNA clone corresponding to a gene specifically expressed in generative cells. The clone was designated *LGC1*. In the differential hybridization approach, a number of cDNA clones were randomly picked from a generative cell cDNA library and cDNA inserts obtained by PCR with λgt11 forward and reverse primers. PCR conditions were 30 cycles of 1 min at 94°C, 2 min at 60°C and 3 min at 72°C with a final extension at 72°C for 10 min. The amplified cDNA inserts were purified, labelled with ^{32}P by random priming (Bresatec Ltd, South Australia) and used for probing of RNA slot blots containing approximately 300 ng of mRNAs from various tissues including leaf, stem, petal, stigma/style, ovary, pollen and generative cells. Hybridization and washing was performed as previously described (18). cDNA clones showing preferential or specific hybridization to generative cell mRNA were selected for further analysis.

The cDNA insert of one clone, *LGC1*, was subcloned into pBluescript(SK)+(Stratagene) and sequenced with ABI PRISM (trademark) dye terminator cycle sequencing kit (Perkin-Elmer). The *LGC1* cDNA insert was shown to be 618 bp in length encoding a predicted gene product of 128 amino acids with a calculated molecular weight of 13.8 kDa (Figure 1). *LGC1* corresponds to a 0.6 kbp transcript which is present at a high level in generative cells as revealed by Northern blot analysis (Figure 2A).

No signal was detectable in the two vegetative tissues tested, leaf and stem, while a faint signal was visible in pollen containing generative cells. The tissue specificity of *LGC1* was further

examined by RT-PCR using gene specific PCR primers that amplify a 0.3 kbp portion of the coding region. For RT-PCR, mRNAs from generative cells and various tissues were reverse transcribed and amplified by PCR with a pair of sequence specific primers (L13A: 5'-GTACTCTTAAGCATACAACATGAG -3' [SEQ ID NO:1]; L13B: 5'-CAGGCATACTTGAATGCTACAAGA-3' [SEQ ID NO:2]) using the Access RT-PCR System (Promega). For each tissue, mRNA was subjected to a serial two-fold dilutions. Based on the signal intensity of the amplified products, the relative amount of *LGC1* mRNA in each tissue was estimated.

RT-PCR amplifications were performed using controlled amount of RNA input from various tissues of lily plant. A PCR product of expected size (0.3 kbp) was obtained in generative cells and pollen but not in all the other tissues tested including vegetative parts such as leaf, stem as well as reproductive parts such as petal, female stigma/style and ovary (Figure 2B). Based on the signal intensity, the inventors estimated that approximately 20 fold more PCR product was obtained when generative cell mRNA was used as compared to pollen mRNA. Since the generative cell constitutes a small portion of pollen, the inventors considered that the amplified *LGC1* product obtained using pollen mRNA input may represent the contribution of generative cell only. Generative cell specificity of *LGC1* was further confirmed by *in situ* hybridization as hereinafter described.

Non-radioactive whole mount *in situ* hybridization was performed in both developing and mature pollen based on the protocols previously described (3, 4, 5). Fresh pollen at various developmental stages was fixed (1% v/v glutaraldehyde in 50 mM PIPES buffer, pH 7.4) for 2 hours at room temperature. The fixed pollen was then washed in buffer and stored in 70% v/v ethanol at 4°C until use. Both sense and antisense riboprobes labelled with DIG-UTP were generated from linearized DNA templates. The hybridization signal was detected with an alkaline phosphatase conjugated anti-DIG antibody using a DIG nucleic acid detection kit (Boehringer Mannheim). To obtain a better resolution, protoplasts of developing pollen were released from exine (the outer wall of pollen) by treatment with enzyme solution (1% w/v Macerozyme, 0.5% w/v Cellulase and 0.5% w/v BSA) as previously described (6). Vegetative and generative nuclei within pollen were visualized by counter-staining with 4′, 6′-diamindino-2-

phenyl indole (DAPI).

The results clearly showed that *LGC1* mRNA is confined to the generative cell in mature pollen (Figure 3). *LGC1* mRNA in pollen as detected by Northern blot and RT-PCR own their origin to the generative cell.

To determine whether *LGC1* mRNA present in the generative cell is the product of generative cell specific gene activity or the result of asymmetric RNA localization and partitioning prior to generative cell formation in developing pollen, the inventors monitored *LGC1* mRNA accumulation during this process. The inventors examined six different developmental stages of generative cells. At the early stage, the newly formed generative cell is attached at one pole of pollen with the vegetative nucleus located in its vicinity (Figures 4A, F). As the development progresses, the generative cell starts to detach itself from the intine (inner cell wall of pollen) while the vegetative nucleus moves towards the centre of pollen (Figures 4B, G). No detectable signal was observed in these two early developmental stages (Figures 4A, B). With rapid size expansion of pollen, the generative cell separates completely from the intine and suspends freely within the vegetative cell cytoplasm. At this stage, its shape becomes elongated with a large nucleus in the centre and most of cytoplasm at both ends of the cell (Figures 4C, H). A weak signal was detected at both ends of the generative cell, indicating the initiation of *LGC1* mRNA transcription (Figures 4C). As the development continues, the generative cell becomes spindle-shaped (Figures 4D, I) and accumulation of *LGC1* mRNA in the generative cell becomes more evident (Figures 4D). At the time of pollen maturity, a very high level of *LGC1* mRNA were observed in the generative cell (Figure 3A, Figures 4E, J). Next, pollen germination occurs on female stigma and pollen tubes grow inside the female stylar tissue. The generative cell then moves into pollen tube and undergoes a mitotic division producing two male gametes, the sperm cells (Figures 4K, L). *LGC1* mRNA was clearly detectable in the two sperm cells inside the pollen tubes (Fig. 4K) as described more fully below.

In lily, generative cell division occurs in the pollen tube during its growth in the female stylar tissue. *In situ* hybridization of mRNA in sperm cells, therefore, can only be performed in pollen tube. Pollen tubes were grown *in vivo* by hand pollinating pistils with freshly collected pollen.

After 48 hours, a 1 cm long segment was taken from the base of the style and cut into two symmetrical halves. Pollen tubes growing in the hollow stylar canal were teased out, fixed and then used for *in situ* hybridization as described above.

No signal was detected in the vegetative cell at any stage of pollen development. These results show that the generative cell specific accumulation of *LGC1* mRNA is due to differential gene activation of generative cell.

Male germ line specific gene expression represents a new aspect of fundamental importance in flowering plants. *LGC1* is the first male germ line specific gene to be identified in flowering plants and thus, the present study of generative cell specific gene expression has important implications in understanding the molecular bases of male gamete development. Several aspects of research can immediately benefit from the availability of this gene and its promoter. For example, selective ablation of the male gametes can be achieved using generative cell specific promoter- cytotoxin fusions. The availability of *LGC1* gene promoter will make it possible to introduce marker genes for monitoring the process of sperm-egg recognition and fusion at molecular level. Furthermore, the male gamete specific promoter may be used to generate a range of transposos to specify tagged pollen genes.

EXAMPLE 2

MALE GAMETE CELL SPECIFIC EXPRESSION OF H2A AND H3 HISTONE GENES

The following Examples shows the identification of two cDNA clones, *gcH2A* and *gcH3*, which encode male gamete-specific variants of histones H2A and H3, respectively. The inventors show that both *gcH2A* and *gcH3* mRNAs accumulate exclusively within the male germ line cell, the generative cell. An examination of the spatial distribution of *gcH2A* and *gcH3* transcripts during pollen development show that initiation of expression of these genes occurs in generative cell at the later stages of pollen maturation. The results indicate that these histone variants are the products of generative cell transcriptional activity. This example provides the first insight of male germ line cell specific histone gene expression in flowering plants.

1. INTRODUCTION

Histones are the major protein constituents of the chromatin of eukaryotic cell nuclei. Histone proteins include five major classes: four core histones, H2A, H2B, H3, H4 and one linker histone H1. The core histones are small, basic proteins (11-15 kDa) that contain a high proportion of positively charged amino acids, mainly lysine and arginine. Histones are highly conserved throughout evolution and are encoded by multigene families. Genes encoding major classes of histones are usually expressed in a cell cycle-dependent fashion at the beginning of the S (DNA synthesis) phase and are co-ordinately regulated at the transcriptional and post-transcriptional level through the cell cycle (7).

2. METHODS

(a) Construction and screening of cDNA library

Generative cells were isolated from mature pollen of lily (*Lilium longiflorum*) as previously described (8) and stored at -70°C until use. Poly(A)+ RNA was isolated from approximately 1 x 10^5 of stored generative cells using oligo (dT)-cellulose affinity column (Pharmacia) according to the manufacture's instruction. First-strand cDNA was synthesized with an oligo (dT) primer. A Capswitch primer was also used to ensure the synthesis of full length clones. The resultant cDNA was amplified by PCR using the following conditions: 35 cycles of 94^0C for 1 min, 42°C for 2 min and 72°C for 2 min. The PCR products were size-fractionated through a Sephadex-50 column and cDNAs of appropriate size were cloned into λgt11 expression vector.

For screening, a number of cDNA clones was randomly picked and cDNA inserts were obtained by PCR with λgt11 forward and reverse primers. Differential screening was conducted by probing RNA slot blots of various tissues with the amplified cDNA inserts. cDNA clones showing strong hybridization to generative cell RNA, weak hybridization to pollen RNA and no hybridization to other tissues were considered to be putative generative cell-specific clones.

(b) Sequencing analysis

The putative generative cell cDNA clones were subcloned into pBluescript II SK+ (Stratagene). Sequencing was performed on both strands by the dideoxy chain-termination method (9) using ABI PRISM (trademark) dye terminator cycle sequencing kit (Perkin-Elmer) with an automated DNA sequencer. Sequence-specific primers were used to generate overlapping sequence information. DNA and protein sequence analysis was performed using BLAST search tools.

(c) RNA gel blot analyses

Total RNA was prepared from various tissues (10). Generative cell RNA was isolated using SNAP RNA extraction kit (Invitro Gene) according to the manufacture's procedure. For gel blot analysis, 20 μg of total RNA was separated by denatured agarose gel electrophoresis, blotted onto Hybond N+ nylon membrane (Amersham) and probed with ^{32}P-labelled *gcH2A* and *gcH3* cDNA inserts. Hybridization of probes with RNA blots was performed in 50% v/v deionised formamide, 2 x SSPE (1 x SSPE is 0.15 M NaCl, 0.01 M NaH_2PO_4, and 1 mM EDTA, pH 7.4), 1% w/v PEG, 0.5% w/v BLOTTO, 7% w/v SDS and 0.5mg/ml denatured salmon sperm DNA at 42°C overnight. The blots were washed with 2 x SSC (1 X SSC is 0.15 M NaCl and 15 mM sodium citrate, pH 7.0), 0.1% w/v SDS at room temperature for 15 min and with 0.2 x SSC, 0.1% w/v SDS at 65°C for 15 min, followed by a brief wash in 0.2 x SSC. The blots were re-probed with lily ribosome RNA to verify the relative amount of RNAs loaded.

(d) *In situ* hybridization

Non-radioactive whole mount *in situ* hybridization was performed based on the protocols described (11, 12, 13). Developmental stages of pollen were determined using 4', 6'-diamidino-2-phenyl indole (DAPI) staining. Mature and developing pollen was treated with an enzyme solution (1% w/v macerozyme, 0.5% w/v cellulase and 0.5% w/v BSA) for 1 hour to remove the exine (the outer wall of pollen). Pollen protoplasts were then washed in 50 mM PIPES buffer and fixed in 1% v/v glutaraldehyde in 50 mM PIPES buffer, pH 7.4, for 2 hours at room temperature. The fixed pollen was then washed in 50 mM PIPES buffer and stored in 70% v/v

ethanol at 4°C.

Prior to hybridization, pollen samples were first dehydrated through an ethanol series up to 100% v/v ethanol. Samples were then treated with xylene (2 x 10 min) followed by rehydration through an ethanol series. Proteinase K (1μg/ml) treatment was carried out in 100 mM Tris-HCl, pH 8 and 50 mM EDTA for 40 min at 37°C. Digoxigenin-labelled riboprobes were synthesized by *in vitro* transcription (Promega). Hybridization was performed in 50% v/v formamide, 6 x SSC, 3% w/v SDS, 100 μg/ml tRNA at 55°C overnight. Samples were then washed in 1 x SSC, 0.1% w/v SDS at room temperature followed by 2 x 10 min washes in 0.2 SSC, 0.1% w/v SDS at 55°C. RNase A (10 μg/ml) treatment was performed in 2 x SSC for 1 hour at 37°C. Hybridization signal was detected using a DIG detection kit (Boehringer Mannheim) according to the manufacture's specification. Vegetative and generative cell nuclei were visualized by counter-staining with DAPI.

RESULTS

Isolation and Characterisation of histone *gcH2A* and *gcH3* cDNA clones

Lily (*Lilum longiflorum*) was used as an experimental system in accordance with the present Example. Within the pollen grain, the male germ line cell (generative cell) is enclosed in the much larger vegetative cell. To maximize the chance of obtaining genes specifically expressed in the generative cell, the inventors prepared a cDNA library using polyA(+) RNA from isolated generative cells. The cDNA library was screened by differential hybridization using probes from generative cells, pollen, leaf, stem, pistil and ovary. cDNA clones that gave strong positive hybridization signal with generative cell mRNA, weak signal with pollen mRNA and no signal with mRNA from other tissues were considered as putative generative cell specific clones. These cDNA clones were subjected to further analysis. Two of these clones were found to encode proteins which were identified as variants of histone H2A and H3, respectively. The two clones were designated *"gcH2A"* and *"gcH3"*.

gcH2A cDNA is 581 bp long and contains an open reading frame of 333 bp starting from the first

ATG at position 49 to a stop codon TAA at position 379 (Figure 1). The derived amino acid sequence of *gcH2A* is composed of 111 amino acids and encodes a protein with a calculated molecular mass of 12.1 kDa. gcH2A polypeptide contains 10.8% arginine and 5.4 % lysine. The deduced amino acid sequence of *gcH2A* shows high levels of sequence similarity as well as variability when compared to somatic H2A histones from other organisms. The N-terminal region of the protein appeared to be more conserved than the C-terminal region. In addition, gcH2A polypeptide is 30-35 amino acids shorter at the C-terminus than somatic H2A histone. It has been reported that the C-terminal variable regions of wheat somatic histones can be of two structural different types (14). Type 1 H2A proteins have one or two copies of a SPKK motif which is known to interact with the minor groove of the DNA, whereas type 2 H2A proteins have a shorter C-terminal variable region and no SPKK motif. Using these criteria, the lily generative cell specific H2A *(gcH2A)* histone can be classified as type 2 since the C-terminal region of *gcH2A* does not contain a SPKK motif.

The complete sequence of the *gcH3* cDNA clone is shown in Figure 6. The *gcH3* cDNA is of 485 nucleotides and contains a putative open reading frame of 336 bp encoding a protein of 112 amino acids. The predicted gcH3 polypeptide, containing 8% arginine and 12.5% lysine, has a calculated molecular mass of 12.5 kDa. When compared to somatic histone H3, the deduced amino acid sequence of *gcH3* exhibits two highly conserved regions located near both terminus of the polypeptide and a variable region of 14 amino acids (position 50 to 64) in the centre region.

Both *gcH2A* and *gcH3* histone clones were transcribed as polyadenylated mRNAs. Sequencing analysis revealed A/T rich regions resembling the polyadenylation consensus signal and polyadenylated tract bases at their 3' ends (Figures 5 and 6).

To determine the expression patterns of *gcH2A* and *gcH3*, RNA blot analysis was performed with RNA samples from various organs including generative cells, pollen grain, young expanding leaf, stem, pistil and ovary. Considering the highly conserved nature of the histone coding region, hybridization and washing were conducted at high stringency to avoid cross hybridizations with other somatic histone mRNAs. mRNAs corresponding to both *gcH2A* and

gcH3 were detected in generative cells (Fig. 7). A weak hybridization signal was also detected in pollen whereas neither vegetative nor other floral tissues tested showed detectable levels of *gcH2A* and *gcH3* mRNAs. Since pollen grains contain both vegetative and generative cells, it was apparent that the fainter signal detected in pollen RNA was due to the contribution of generative cell only. The inventors tested young leaf and stem tissues from seedlings which have a large number of dividing cells by RNA gel blot as well as RT-PCR analyses. No expression, neither of *gcH2A* nor of *gcH3* was detected. Since the tissues tested represent a broad spectrum of plant organs, it was concluded that both *gcH2A* and *gcH3* are expressed in generative cells only. From the intensity of the hybridization signal, it can be assumed that *gcH2A* is a highly abundant gene, whereas *gcH3* represents a lowly expressed transcript.

The inventors examined the spatial distribution of *gcH2A* and *gcH3* mRNAs within pollen by *in situ* hybridization. Digoxigenin (DIG) labelled *gcH2A* and *gcH3* were used to probe whole-mount pollen grains. Accumulation of both *gcH2A* and *gcH3* mRNAs were clearly confined to the generative cell of pollen whereas no hybridization signal was detected in the vegetative cells of pollen (Figures 8a, c). No signal was observed in pollen grain probed with control sense probes (Figures 8b, d). The accumulation of *gcH2A* in the generative cell appeared much higher than that of *gcH3*. The results obtained by *in situ* hybridization correspond to those of RNA gel blot analysis and clearly demonstrate the generative cell specificity of both *gcH2A* and *gcH3*.

To determine the temporal expression of *gcH2A* and *gcH3*, the inventors examined five developmental stages of male gametogenesis. It is well established that three DNA replications occur during male gametogenesis of flowering plants. The first replication occurs prior to meiosis in the microsporocyte or pollen mother cell which produces a tetrad of four haploid microspores. The second replication occurs in the microspore before the first mitotic division (pollen mitosis I) which produces a large vegetative cell and a small generative cell. The third replication takes place in the generative cell before the second mitosis (pollen mitosis II) which results in the formation of two male gametes (sperm cells). To determine whether *gcH2A* and *gcH3* are associated with any of these three DNA replications during male gametogenesis, the inventors performed *in situ* hybridization in microsporocyte, microspore and three stages of

generative cell development. No hybridization signal was observed in pre-meiotic microsporocytes and pre-mitotic microspores. Further, no *gcH2A* and *gcH3* mRNAs were detected in the newly formed generative cell soon after pollen mitosis I (Figures 9a, d, g). As development progresses into pollen maturation, the generative cell completely separates from the intine wall of pollen and suspends freely within the vegetative cell cytoplasm. At this stage, the generative cell becomes elongated and spindle-shaped with a large nucleus in the centre and most of its cytoplasm at both ends (Figures 9b, e, h). A weak signal was observed at both ends of the generative cell when probing with *gcH2A*, indicating the initiation of *gcH2A* mRNA transcription (Figure 9b). At the time of pollen maturity, the accumulation of *gcH2A* mRNA in the generative cell reached a very high level as indicated by the strong hybridization signal (Figure 7c). In comparison to this, the signal obtained with *gcH3* probe appeared much weaker (Figure 7i), and mRNA corresponding to the *gcH3* clone could only be detected at the mature stage of pollen development.

EXAMPLE 3

CLONING OF PROMOTER REGION OF LGC1

The promoter region of LGC1 was obtained by using the method of Uneven PCR [18]. A gene specific primer and an arbitrary primer were used to generate fragments directly from genomic DNA of lily. Two rounds of PCR amplification were performed.

For the first round of Uneven PCR, a LGC1 gene specific primer (5′-CAGGCATACTTGAATGCTACAAGA-3′ [SEQ ID NO:10]) and an arbitrary 10-mer primer were used. 0.05 μM 10-mer primer, 0.25 μM gene specific primer, 20 ng lily genomic DNA, 200 μM dNTP and 2 units AmpliTaq were added in the 40 μl reaction mix. Cycling conditions of Uneven PCR were 94°C for 1 min, then for cycle 1, 94°C for 30 sec, 55°C for 1 min, 72°C for 1 min, for cycle 2, 94°C for 30 sec, 42°C for 1 min, 72°C for 1 min; cycle 1 and 2 were repeated 3 times. Then for cycle 7, 94°C for 15 sec, 57°C for 30 sec, 72°C for 30 sec; for cycle 8, 94°C for 15 sec, 45°C for 30 sec, 72°C for 30 sec, cycle 7 and 8 were repeated 20 times. Finally, the sample was held at 72°C for 5 min. A portion (0.5 μl) of the products from the first round were used as templates for the second round of Uneven PCR. All the components were the same as

in the first round except that a nested specific primers (5′-TGTGAACCATACAGAAGAGAACGC-3′ [SEQ ID NO:11]) were used to replace the first specific primer. The cycling conditions were: 94°C for 1 min; then for cycle 1, 94°C for 15 sec, 57°C for 30 sec, 72°C for 30 sec; for cycle 2, 94°C for 15 sec, 45°C for 30 sec, 72°C for 30 sec, cycle 1 and 2 were repeated 20 times; Finally, 72°C for 5 min.

The samples were size fractionated on 1% w/v agarose gel and blotted on a nylon membrane. The blot was probed with ^{32}P labelled-LGC1 cDNA. The bands hybridized to LGC1 cDNA were then subcloned into pGEM T-vector. DNA sequencing was performed on both strands by the dideoxy chain-termination method using ABI PRISM™ dye terminator cycle sequencing kit with an automated DNA sequencer.

The nucleotide sequence for the LGC1 promoter is shown in SEQ ID NO:9 and in Figure 10. The transcription start site is nucleotide position 817 and the translation start site (ATG) is nucleotide position 894.

EXAMPLE 4
CONSTRUCTS COMPRISING THE LGC1 PROMOTER

A variety of genetic constructs are made comprising the LGC1 promoter, a nucleotide sequence operably linked thereto and a reporter genetic sequence. Some of these constructs are shown in Figure 11.

EXAMPLE 5
GENERATIVE CELL SPECIFIC EXPRESSION OF LGC1 IN TRANSGENIC TOBACCO

To ascertain that the 5′ non-coding region of *LGC1* represents an active promoter and to study its expression pattern, 894 bp of *LGC1* upstream sequence were fused to the *Escherichia coli* β-glucuronidase *(Gus)* reporter gene (Fig. 12A). The chimaeric fusion construct was introduced into *Nicotiana tabacum* by *Agrobacterium*-mediated transformation. Several independent

transformants were obtained. Histochemical and fluorimetrical analysis of the transgenic plants for GUS enzyme activity demonstrated that 894 bp flanking region of *LGC1* were sufficient to direct gene expression in a generative cell specific manner. None of the transformants showed blue staining in vegetative tissues, like stem, leaf and root, or in different parts of the flower, such as petals, sepals, pistils and ovaries. Counterstaining of mature pollen with DAPI confirmed that *Gus* gene expression was clearly restricted to the generative cell. The observed activity of the *LGC1* 5'-flanking region thus reflects the expression of endogenous *LGC1* in lily pollen. The results are shown in Figure 12B.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

1. Honma, M.A. *et al. Proc. Natl. Acad. Sci. USA 90:* 6242-6246, 1993.
2. Xu, H. *et al. Gene 164:* 255-259, 1995.
3. Bouget, F. *et al. J. Phycol. 31:* 1027-1030, 1995.
4. Bouget, F. *et al. Plant Cell 8:* 189-201, 1996.
5. Torres, M *et al. Plant J. 8:* 317-321, 1995.
6. Blomstedt, C.K. *et al. Plant Mol. Biol. 31:* 1083-1086, 1996.
7. Osley, M.A. *Annu. Rev. Biochem. 60:* 827- , 1991.
8. Tanaka, I. *Protoplasma 142:* 68-73, (1988)
9. Sanger, F. *et al. Proc. Natl. Acad. Sci. USA 74:* 5463-5467, 1977.
10. Chomczynski, P. *et al. Anal. Biochem. 162:* 156-159, 1987.
11. Bouget, F. *et al. J. Phycol. 31:* 1027-1030, 1995.
12. Terres, M.A. *et al. Plant J. 8:* 317-321, 1995.
13. Bouget, F. *et al. Plant Cell 8:* 189-201, 1996.
14. Huh, H.G. *et al. Plant Mol. Biol. 33:* 791-802, 1997.
15. Rommens, C.M.T. *et al. Mol. Gene. Genet. 231:* 433-441, 1992.
16. Roberts, M. In Plant Gene Isolation: Principles and Practice, Ed. by C.D. Foster and D. Twell, pp 301-328, 1996, John Wiley & Sons Ltd.
17. McCormick, S. *Plant Cell 5:* 1265-1275, 1993.
18. Chen, X and Wu, R *Gene 185:* 195-199, 1997.
19. Marmur, J and Doty, P. *J. Mol. Biol. 5:* 109, 1962.
20. Bonner, W. M. and Laskey, R. A. *Eur. J. Biochem. 46:* 83, 1974.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: (OTHER THAN US): THE UNIVERSITY OF MELBOURNE
(US ONLY): SINGH Mohan, BHALLA Prem, HUI-LING Xu and SWOBODA Ines

(ii) TITLE OF INVENTION: NOVEL NUCLEIC ACID MOLECULES AND USES THEREFOR

(iii) NUMBER OF SEQUENCES: 9

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: DAVIES COLLISON CAVE
(B) STREET: 1 LITTLE COLLINS STREET
(C) CITY: MELBOURNE
(D) STATE: VICTORIA
(E) COUNTRY: AUSTRALIA
(F) ZIP: 3000

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT INTERNATIONAL
(B) FILING DATE: 24-JUL-1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: PO8233
(B) FILING DATE: 25-JUL-1997
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: PP1184
(B) FILING DATE: 31-DEC-1997
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: HUGHES, DR E JOHN L
(C) REFERENCE/DOCKET NUMBER: EJH/AF

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: +61 3 9254 2777
(B) TELEFAX: +61 3 9254 2770
(C) TELEX: AA 31787

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTACTCTTAA GCATACAACA TGAG 14

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CAGGCATACT TGAATGCTAC AAGA 14

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 625 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 82..468

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
GCCATCCCAT CAACAGAAGG TTTAAGTGGA AATCCATTTC ATTAGAAAAG ATCGGACAAA      60

GGGTACTCTT AAGCATACAA C ATG AGG GCG GTG GCG GTT TTC TTT GCT TGC        111
                         Met Arg Ala Val Ala Val Phe Phe Ala Cys
                           1               5                  10

GTT CTC TTC TGT ATG GTT CAC AAA GCC GCA CTT GCG GAT GAT AAA ACG        159
Val Leu Phe Cys Met Val His Lys Ala Ala Leu Ala Asp Asp Lys Thr
                 15                  20                  25

TGC AAC CCT ACA GAT TTT ATG GTT ACC CAA ACC ATA ACT GGA TTG ACA        207
```

```
Cys Asn Pro Thr Asp Phe Met Val Thr Gln Thr Ile Thr Gly Leu Thr
                30                  35                  40

ATC GGC GGT AAA CAA GAG TTC GAG GTC AAT TTA ATA AAC AAT TTG TAT      255
Ile Gly Gly Lys Gln Glu Phe Glu Val Asn Leu Ile Asn Asn Leu Tyr
        45                  50                  55

TGT GCA CAA TCT AAT GTC AAA GTT TCA TGT GAC GGG CTT CAT ACC ACC      303
Cys Ala Gln Ser Asn Val Lys Val Ser Cys Asp Gly Leu His Thr Thr
    60                  65                  70

GAA CCA ATA GAT CCT CAC ATT ATC AGA CCA CTT AGT GAC GGA ACG AAC      351
Glu Pro Ile Asp Pro His Ile Ile Arg Pro Leu Ser Asp Gly Thr Asn
75                  80                  85                  90

AAC TGC CTT GTC AAC AAT GGA GCG CCT ATT TCT CAT GCT ACT CTT GTA      399
Asn Cys Leu Val Asn Asn Gly Ala Pro Ile Ser His Ala Thr Leu Val
                95                  100                 105

GCA TTC AAG TAT GCC TGG GAT GTT CCT CCA TCT TTC AGC ATC ATC AGC      447
Ala Phe Lys Tyr Ala Trp Asp Val Pro Pro Ser Phe Ser Ile Ile Ser
            110                 115                 120

TCT GAT ATA AAT TGC TCC TAA GGAGAAA ATTCTAGTTG GCAGAGAATA            495
Ser Asp Ile Asn Cys Ser OCH
        125

ATCATATAGT CTTTTTTACT GAGCTATTTA ATTTTTTCAA TTTTCACCAA TAAGATTATT    555

TTAATGGAAT GTTAATGTAT TAGAATTGAA AAATAAAAAA AAAAAAAAAA AAAAAAAAAA    615

AAAAAAAAAA                                                           625
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 128 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Met Arg Ala Val Ala Val Phe Phe Ala Cys Val Leu Phe Cys Met Val
  1               5                  10                  15

His Lys Ala Ala Leu Ala Asp Asp Lys Thr Cys Asn Pro Thr Asp Phe
            20                  25                  30

Met Val Thr Gln Thr Ile Thr Gly Leu Thr Ile Gly Gly Lys Gln Glu
        35                  40                  45

Phe Glu Val Asn Leu Ile Asn Asn Leu Tyr Cys Ala Gln Ser Asn Val
    50                  55                  60

Lys Val Ser Cys Asp Gly Leu His Thr Thr Glu Pro Ile Asp Pro His
65                  70                  75                  80

Ile Ile Arg Pro Leu Ser Asp Gly Thr Asn Asn Cys Leu Val Asn Asn
                85                  90                  95

Gly Ala Pro Ile Ser His Ala Thr Leu Val Ala Phe Lys Tyr Ala Trp
            100                 105                 110

Asp Val Pro Pro Ser Phe Ser Ile Ile Ser Ser Asp Ile Asn Cys Ser OCH
```

115 120 125

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 587 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 49..378

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
GAAAGTTGAA ACATCTCCAT CAAACTCTAG AGTCAGATTT CCCACAAG ATG ATT TCA      57
                                                    Met Ile Ser
                                                     1

TCG GCA AAT AAC AAA GGC GCC GGC ACA AGC CGC CGC AAG CTC CGT TCT      105
Ser Ala Asn Asn Lys Gly Ala Gly Thr Ser Arg Arg Lys Leu Arg Ser
  5                  10                  15

GAG AAG GCT GCA CTC CAG TTC TCC GTC AGT CGC GTC GAA TAC TCC CTC      153
Glu Lys Ala Ala Leu Gln Phe Ser Val Ser Arg Val Glu Tyr Ser Leu
 20                  25                  30                  35

AAG AAG GGG CGC TAT TGC AGG CGC TTA GGC GCT ACG GCC CCC GTC TAC      201
Lys Lys Gly Arg Tyr Cys Arg Arg Leu Gly Ala Thr Ala Pro Val Tyr
                 40                  45                  50

CTA GCC GCC GTC CTT GAA AAC CTC GTG GCC GAA GTG TTG GAC ATG GCG      249
Leu Ala Ala Val Leu Glu Asn Leu Val Ala Glu Val Leu Asp Met Ala
             55                  60                  65

GCG AAC GTG ACA GAA GAA ACA TCC CCC ATT GTT ATC AAA CCG AGG CAT      297
Ala Asn Val Thr Glu Glu Thr Ser Pro Ile Val Ile Lys Pro Arg His
         70                  75                  80

ATT ATG CTT GCC CCC AGG AAT GAT GTA GAA GTT GAA CAA GCT GTT TCA      345
Ile Met Leu Ala Pro Arg Asn Asp Val Glu Val Glu Gln Ala Val Ser
  85                  90                  95

CGG TGT CAC CAT CTC GGC ATC AGG TGT CGT CCC TAAAACACGC AAAGAGCTGG    398
Arg Cys His His Leu Gly Ile Arg Cys Arg Pro
100                 105                 110

ACCGTCGCAA ACGCCGTTCC ACCTTTCAGC CGGATTAGTT CTTGATATTT CATTCTATCA    458

ATCTTGGTTA TGTGACTGTG ATTTTTCGTT TTGTGTTGAA CTAAGCCCCC TAATCTGGAT    518

TTCTCGTTTT ATGTTGAACT AAGTCTGTGC ACTCTTGAAG TAAAAAAAAA AAAAAAAAAA    578

AAAAAAAAA                                                            587
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Ile Ser Ser Ala Asn Asn Lys Gly Ala Gly Thr Ser Arg Arg Lys
 1               5                  10                  15

Leu Arg Ser Glu Lys Ala Ala Leu Gln Phe Ser Val Ser Arg Val Glu
            20                  25                  30

Tyr Ser Leu Lys Lys Gly Arg Tyr Cys Arg Arg Leu Gly Ala Thr Ala
        35                  40                  45

Pro Val Tyr Leu Ala Ala Val Leu Glu Asn Leu Val Ala Glu Val Leu
    50                  55                  60

Asp Met Ala Ala Asn Val Thr Glu Glu Thr Ser Pro Ile Val Ile Lys
65                  70                  75                  80

Pro Arg His Ile Met Leu Ala Pro Arg Asn Asp Val Glu Val Glu Gln
                85                  90                  95

Ala Val Ser Arg Cys His His Leu Gly Ile Arg Cys Arg Pro
            100                 105                 110
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 485 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 16..348

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
GATCCCAAAT CATCA ATG ACG ATC CCC GAA AAG AAA TCC GTC GCT CCG ATG      51
                 Met Thr Ile Pro Glu Lys Lys Ser Val Ala Pro Met
                   1               5                  10

GCC CGT ATG AAG CAT ACA GCC CGC ATG TCT ACC GGC GGT AAG GCT CCA      99
Ala Arg Met Lys His Thr Ala Arg Met Ser Thr Gly Gly Lys Ala Pro
          15                  20                  25

CGC AAG CAG CTC GCC TCT AAG GCT CTT CGC AAG GCG CCA CCA CCA CCG     147
Arg Lys Gln Leu Ala Ser Lys Ala Leu Arg Lys Ala Pro Pro Pro Pro
      30                  35                  40

ACC AAA GGA GTG AAG CAG CCC ACC ACT ACC ACC TCC GGA AAA TGG CGC     195
Thr Lys Gly Val Lys Gln Pro Thr Thr Thr Thr Ser Gly Lys Trp Arg
 45                  50                  55                  60

TTC GCG AGA TTT CAC AGG AAA CTG CCA TTC CAA GGG CTG GTG AGG AAA     243
Phe Ala Arg Phe His Arg Lys Leu Pro Phe Gln Gly Leu Val Arg Lys
                 65                  70                  75
```

```
ATC TGG CAG GAC TTG AAG ACA CAT CTG CGC TTC AAG AAC CAC TCG GTT        291
Ile Trp Gln Asp Leu Lys Thr His Leu Arg Phe Lys Asn His Ser Val
            80                  85                  90

CCT CCA CTT GAG GAG GTA ACT GAG GTT TAT CCT TGC CAA ACT ATT GGA        339
Pro Pro Leu Glu Glu Val Thr Glu Val Tyr Pro Cys Gln Thr Ile Gly
        95                  100                 105

GGA TGC TAT TAGGATATTG AATTTGGATA ATGGTTTAAT TATCTGTTCT                 388
Gly Cys Tyr
    110

ACCTTTATGA TCAAATTTCT GTGGCTCAGC GTTGTGTAAT TTGGGCAATC GAATTCTTAG      448

CTATATTGCC TCAAAAAAAA AAAAAAAAAA AAAAAAA                               485
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Met Thr Ile Pro Glu Lys Lys Ser Val Ala Pro Met Ala Arg Met Lys
 1               5                  10                  15

His Thr Ala Arg Met Ser Thr Gly Gly Lys Ala Pro Arg Lys Gln Leu
            20                  25                  30

Ala Ser Lys Ala Leu Arg Lys Ala Pro Pro Pro Pro Thr Lys Gly Val
        35                  40                  45

Lys Gln Pro Thr Thr Thr Thr Ser Gly Lys Trp Arg Phe Ala Arg Phe
    50                  55                  60

His Arg Lys Leu Pro Phe Gln Gly Leu Val Arg Lys Ile Trp Gln Asp
65                  70                  75                  80

Leu Lys Thr His Leu Arg Phe Lys Asn His Ser Val Pro Pro Leu Glu
                85                  90                  95

Glu Val Thr Glu Val Tyr Pro Cys Gln Thr Ile Gly Gly Cys Tyr
            100                 105                 110
```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 945 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GGAGGGTGTT GGAATTAGGT TTGCCTAGGG TTTGCCTAGG TTTAGAGAAA TAGTCAAAAT 60

TGTCCTATTC TATAGGCATG ATTTAGTAGT GAGTTAATTA TCCTATAATT TCTCTTCTTG 120

TATGCTCAAA TAACTGGTTC TTTAATGAAT AGATAATTAA GTTTTGTAGC AATTTCTTCC 180

TCAAATTGAG TATCAACAAT TGTTAGATTG CTTTGGTGAT TATATTTGAT ATAATTGTTT 240

GTAAGAATGT GTAGTGAAAA GATTGTGATT ATTCATTTCG TTGTTGGACG AATTGTTAGA 300

GCCCCATCGC TAATGCCTTA TAGTACTCGA AATATGTTGG GAATAGAAGA TGAAAAATCC 360

CATTCTTTGT AGTAGGAGTA AAAATTTGTC TTTTCATTAT TCCATTGAAT GTTAACCACT 420

TGCCATTCAT CTGACGGGGA TGGCAGAGTT CCGACCATCT AGTGATCCGT GGGATATTGA 480

TTTTGGTGTG TCAATGAAAT TGTGAGAACG GGCTTCTGGG AGAGAAAAGC CCTCTTGCCT 540

CTGATATGAA CACTGAGGCT GATTATGTTA ACGGATGGAG ATTTATCAGT GGCTGAATTT 600

GGGTGCTGTA GAGACAGAAT TTGAAAGTTC TAACAATAAA CCCTAATTCT GAACTTGGGC 660

GGGGCTGGGA TTTTACTCTT AACGTGAAGA GAGGCAAGAT GAATTGACAG CTTGGAAGTC 720

GATCCAGTAT TTGCAGCAGT CGTGACGAAT TGGTTGGACA GTTACATCGG TCAGAGAATG 780

CGTTCTATAA ATTCCCCCAA TGCGGCAGTG AAAATCCCAT CCCATCAACA GAAGTTTTAA 840

GTGGAAACCC ATTCCAATAG AGAAGATCGA ACAAAGGGTA TTTAAACATA CAAATGGGGG 900

CAGTGGTGTT TCTTTTTGCT TGCGTTCTCT TCTGTATGGT TCACA 945

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CAGGCATACT TGAATGCTAC AAGA 14

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TGTGAACCAT ACAGAAGAGA ACGC 24

CLAIMS:

1. An isolated nucleic acid molecule comprising a nucleotide sequence or a complementary nucleotide sequence corresponding to a gene or derivative thereof or a region of said gene facilitating its expression wherein said gene is specifically expressed in generative cells and sperm cells of a plant.

2. An isolated nucleic acid molecule according to claim 1 wherein said plant is selected from a legume, crop plant, cereal plant, a grass, a fruiting plant and a flowering plant.

3. An isolated nucleic acid molecule according to claim 2 wherein the plant is a lily or a related plant.

4. An isolated nucleic acid molecule according to claim 3 comprising a nucleotide sequence which encodes an amino acid sequence selected from SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 or an amino acid sequence having at least 40% identity to any one of SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.

5. An isolated nucleic acid molecule according to claim 4 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 or a nucleotide sequence having at least 50% identity to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 or is a nucleotide sequence capable of hybridizing to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7 under low stringency conditions at 42°C.

6. An isolated nucleic acid molecule according to claim 1 or 3 wherein said nucleic acid molecule is a promoter or a functional derivative which directs plant generative cell and sperm cell specific expression.

7. An isolated nucleic acid molecule according to claim 6 comprising a nucleotide sequence or complementary nucleotide sequence which is capable of hybridizing under low stringency conditions at 42°C to a genomic region encompassing at least about 2 kbp upstream of the

genomic nucleotide sequence corresponding to any one of SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:7.

8. An isolated nucleic acid molecule according to claim 6 comprising a nucleotide sequence or complementary nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9.

9. An isolated nucleic acid molecule comprising a nucleotide sequence or complementary nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9 and wherein said nucleic acid molecule is capable of directing plant generative cell and sperm cell specific expression of a nucleotide sequence operably linked thereto.

10. An isolated nucleic acid molecule according to claim 9 wherein the nucleotide sequence operably linked to the nucleic acid molecule encodes or defines GUS, GFP, a ribonuclease, DTA, an antisense molecule, a transposon or a lethal gene.

11. A method of inducing or otherwise facilitating male sterility in a plant, said method comprising operably linking a cytotoxic nucleic acid molecule to a promoter which directs plant generative cell and sperm cell specific expression in said plant such that upon direction by said promoter, the cytotoxic nucleic acid molecule is expressed to produce a product which inactivates, kills or otherwise renders substantially non-functional generative cells and/or sperm cells in said plant.

12. A method according to claim 11 wherein said plant is a legume, crop plant, cereal plant, a grass, a fruiting plant and a flowering plant.

13. A method according to claim 11 wherein the cytotoxic nucleic acid molecule encodes or comprise a cytotoxic protein, an antisense molecule to a particular gene, a ribozyme or a

plantabody.

14. A method according to claim 11 wherein the promoter corresponds to a nucleotide sequence which hybridizes under low stringency conditions to a genomic region comprising at least about 2kbp upstream of a gene corresponding to any one of SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7.

15. A method according to claim 14 wherein the promoter comprises a nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9.

16. A genetic construct comprising a generative cell and sperm cell specific promoter operably linked to a transposase gene, said transposase gene capable of inducing transposition of a transposable element such that upon expression of said promoter, the transposase gene is expressed facilitating transposition of said transposable element.

17. A genetic construct according to claim 16 wherein where the promoter comprises a nucleotide sequence substantially as set forth in SEQ ID NO:9 or a nucleotide sequence capable of hybridizing thereto under low stringency conditions at 42°C or a nucleotide sequence having at least 50% identity to SEQ ID NO:9.

18. A genetic construct according to claim 16 or 17 wherein the transposase gene is the activator (Ac) transposase.

19. A male sterile plant generated by the method of any one of claims 11 to 15.

20. A male sterile plant according to claim 19 which provides seedless fruit or fruit with reduced seed content.



FIG 1

FIGURE 1 (I)

```
GCCATCCCAT CAACAGAAGG TTTAAGTGGA AATCCATTTC ATTAGAAAAG          50

ATCGGACAAA GGGTACTCTT AAGCATACAA C ATG AGG GCG GTG GCG          96
                                   Met Arg Ala Val Ala
                                                    5

GTT TTC TTT GCT TGC GTT CTC TTC TGT ATG GTT CAC AAA GCC         138
Val Phe Phe Ala Cys Val Leu Phe Cys Met Val His Lys Ala
                10                  15

GCA CTT GCG GAT GAT AAA ACG TGC AAC CCT ACA GAT TTT ATG         180
Ala Leu Ala Asp Asp Lys Thr Cys Asn Pro Thr Asp Phe Met
 20                 25                  30

GTT ACC CAA ACC ATA ACT GGA TTG ACA ATC GGC GGT AAA CAA         222
Val Thr Gln Thr Ile Thr Gly Leu Thr Ile Gly Gly Lys Gln
     35                 40                  45

GAG TTC GAG GTC AAT TTA ATA AAC AAT TTG TAT TGT GCA CAA         264
Glu Phe Glu Val Asn Leu Ile Asn Asn Leu Tyr Cys Ala Gln
         50                 55                  60
```

FIGURE 1 (II)

```
TCT AAT GTC AAA GTT TCA TGT GAC GGG CTT CAT ACC ACC GAA          306
Ser Asn Val Lys Val Ser Cys Asp Gly Leu His Thr Thr Glu
            65                  70                  75

CCA ATA GAT CCT CAC ATT ATC AGA CCA CTT AGT GAC GGA ACG          348
Pro Ile Asp Pro His Ile Ile Arg Pro Leu Ser Asp Gly Thr
                80                  85

AAC AAC TGC CTT GTC AAC AAT GGA GCG CCT ATT TCT CAT GCT          390
Asn Asn Cys Leu Val Asn Asn Gly Ala Pro Ile Ser His Ala
 90                  95                 100

ACT CTT GTA GCA TTC AAG TAT GCC TGG GAT GTT CCT CCA TCT          432
Thr Leu Val Ala Phe Lys Tyr Ala Trp Asp Val Pro Pro Ser
    105                 110                 115

TTC AGC ATC ATC AGC TCT GAT ATA AAT TGC TCC TAA                  468
Phe Ser Ile Ile Ser Ser Asp Ile Asn Cys Ser OCH
        120                 125

GGAGAAA ATTCTAGTTG GCAGAGAATA ATCATATAGT CTTTTTTACT              515
```

FIGURE 1 (III)

GAGCTATTTA ATTTTTTCAA TTTTCACCAA TAAGATTATT TTAATGGAAT 565

GTTAATGTAT TAGAATTGAA AAATAAAAAA AAAAAAAAAA AAAAAAAAAA 615

AAAAAAAAAA 625


A
GCs
Leaf
Pollen
Stem
0.8 kb
0.53 kb
B
Generative cells
Pollen
16
32
64
128
256
512
1024
2048
4096
16
32
64
128
256
512
1024
2048
4096
1 Leaf
1 Stem
1 Petal
1 Stigma/style
1 Ovary
- mRNA
0.53 kb
0.12 kb

FIG 2



FIG 3



FIG 4



FIG 5

FIGURE 5 (I)

```
GAAAGTTGAA ACATCTCCAT CAAACTCTAG AGTCAGATTT CCCACAAG                    48

ATG ATT TCA TCG GCA AAT AAC AAA GGC GCC GGC ACA AGC                    87
Met Ile Ser Ser Ala Asn Asn Lys Gly Ala Gly Thr Ser
                  5                  10

CGC CGC AAG CTC CGT TCT GAG AAG GCT GCA CTC CAG TTC                   126
Arg Arg Lys Leu Arg Ser Glu Lys Ala Ala Leu Gln Phe
     15                  20                  25

TCC GTC AGT CGC GTC GAA TAC TCC CTC AAG AAG GGG CGC                   165
Ser Val Ser Arg Val Glu Tyr Ser Leu Lys Lys Gly Arg
            30                  35

TAT TGC AGG CGC TTA GGC GCT ACG GCC CCC GTC TAC CTA                   204
Tyr Cys Arg Arg Leu Gly Ala Thr Ala Pro Val Tyr Leu
 40                  45                  50

GCC GCC GTC CTT GAA AAC CTC GTG GCC GAA GTG TTG GAC                   243
Ala Ala Val Leu Glu Asn Leu Val Ala Glu Val Leu Asp
        55                  60                  65
```

FIGURE 5 (II)

```
ATG GCG GCG AAC GTG ACA GAA GAA ACA TCC CCC ATT GTT          282
Met Ala Ala Asn Val Thr Glu Glu Thr Ser Pro Ile Val
                70                  75

ATC AAA CCG AGG CAT ATT ATG CTT GCC CCC AGG AAT GAT          321
Ile Lys Pro Arg His Ile Met Leu Ala Pro Arg Asn Asp
     80                  85                  90

GTA GAA GTT GAA CAA GCT GTT TCA CGG TGT CAC CAT CTC          360
Val Glu Val Glu Gln Ala Val Ser Arg Cys His His Leu
            95                  100

GGC ATC AGG TGT CGT CCC TAAAACACGC AAAGAGCTGG                398
Gly Ile Arg Cys Arg Pro
105                 110

ACCGTCGCAA ACGCCGTTCC ACCTTTCAGC CGGATTAGTT CTTGATATTT       448

CATTCTATCA ATCTTGGTTA TGTGACTGTG ATTTTTCGTT TTGTGTTGAA       498
```

FIGURE 5 (III)

CTAAGCCCCC TAATCTGGAT TTCTCGTTTT ATGTTGAACT AAGTCTGTGC 548

ACTCTTGAAG TAAAAAAAAA AAAAAAAAAA AAAAAAAAA 587



FIG 6

FIGURE 6 (I)

```
GATCCCAAAT CATCA ATG ACG ATC CCC GAA AAG AAA TCC GTC                42
                 Met Thr Ile Pro Glu Lys Lys Ser Val
                   1               5

GCT CCG ATG GCC CGT ATG AAG CAT ACA GCC CGC ATG TCT                81
Ala Pro Met Ala Arg Met Lys His Thr Ala Arg Met Ser
 10                  15                  20

ACC GGC GGT AAG GCT CCA CGC AAG CAG CTC GCC TCT AAG               120
Thr Gly Gly Lys Ala Pro Arg Lys Gln Leu Ala Ser Lys
         25                  30                  35

GCT CTT CGC AAG GCG CCA CCA CCA CCG ACC AAA GGA GTG               159
Ala Leu Arg Lys Ala Pro Pro Pro Pro Thr Lys Gly Val
                 40                  45

AAG CAG CCC ACC ACT ACC ACC TCC GGA AAA TGG CGC TTC               198
Lys Gln Pro Thr Thr Thr Thr Ser Gly Lys Trp Arg Phe
     50                  55                  60
```

FIGURE 6 (II)

```
GCG AGA TTT CAC AGG AAA CTG CCA TTC CAA GGG CTG GTG                237
Ala Arg Phe His Arg Lys Leu Pro Phe Gln Gly Leu Val
                65                  70

AGG AAA ATC TGG CAG GAC TTG AAG ACA CAT CTG CGC TTC                276
Arg Lys Ile Trp Gln Asp Leu Lys Thr His Leu Arg Phe
 75                  80                  85

AAG AAC CAC TCG GTT CCT CCA CTT GAG GAG GTA ACT GAG                315
Lys Asn His Ser Val Pro Pro Leu Glu Glu Val Thr Glu
        90                  95                 100

GTT TAT CCT TGC CAA ACT ATT GGA GGA TGC TAT                        348
Val Tyr Pro Cys Gln Thr Ile Gly Gly Cys Tyr
            105

TAGGATATTG AATTTGGATA ATGGTTTAAT TATCTGTTCT ACCTTTATGA             398

TCAAATTTCT GTGGCTCAGC GTTGTGTAAT TTGGGCAATC GAATTCTTAG             448

CTATATTGCC TCAAAAAAAA AAAAAAAAAA AAAAAAA                          485
```


Leaf
Stem
Generative cell
Pistil
Pollen
Ovary
gcH2A
— 0.56kb
gcH3
— 0.56kb
rRNA

FIG 7



FIG 8



FIG 9



FIG 10

FIGURE 10 (I)

```
GGAGGGTGTT GGAATTAGGT TTGCCTAGGG TTTGCCTAGG TTTAGAGAAA      50
TAGTCAAAAT TGTCCTATTC TATAGGCATG ATTTAGTAGT GAGTTAATTA     100
TCCTATAATT TCTCTTCTTG TATGCTCAAA TAACTGGTTC TTTAATGAAT     150
AGATAATTAA GTTTTGTAGC AATTTCTTCC TCAAATTGAG TATCAACAAT     200
TGTTAGATTG CTTTGGTGAT TATATTTGAT ATAATTGTTT GTAAGAATGT     250
GTAGTGAAAA GATTGTGATT ATTCATTTCG TTGTTGGACG AATTGTTAGA     300
GCCCCATCGC TAATGCCTTA TAGTACTCGA AATATGTTGG GAATAGAAGA     350
TGAAAAATCC CATTCTTTGT AGTAGGAGTA AAAATTTGTC TTTTCATTAT     400
TCCATTGAAT GTTAACCACT TGCCATTCAT CTGACGGGGA TGGCAGAGTT     450
CCGACCATCT AGTGATCCGT GGGATATTGA TTTTGGTGTG TCAATGAAAT     500
TGTGAGAACG GGCTTCTGGG AGAGAAAAGC CCTCTTGCCT CTGATATGAA     550
CACTGAGGCT GATTATGTTA ACGGATGGAG ATTTATCAGT GGCTGAATTT     600
GGGTGCTGTA GAGACAGAAT TTGAAAGTTC TAACAATAAA CCCTAATTCT     650
GAACTTGGGC GGGGCTGGGA TTTTACTCTT AACGTGAAGA GAGGCAAGAT     700
GAATTGACAG CTTGGAAGTC GATCCAGTAT TTGCAGCAGT CGTGACGAAT     750
```

FIGURE 10 (II)

TGGTTGGACA GTTACATCGG TCAGAGAATG CGTTCTATAA ATTCCCCCAA 800

TGCGGCAGTG AAAATC**C**CAT CCCATCAACA GAAGTTTTAA GTGGAAACCC 850

ATTCCAATAG AGAAGATCGA ACAAAGGGTA TTTAAACATA CAA**ATG**GGGG 900

CAGTGGTGTT TCTTTTTGCT TGCGTTCTCT TCTGTATGGT TCACA 945

FIG 11


GUS
LGC1 promoter
Selectable marker gene
GFP
LGC1 promoter
Selectable marker gene
Ribonuclease
LGC1 promoter
Selectable marker gene
DTA
LGC1 promoter
Selectable marker gene

A

B



FIG 12

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 98/00587

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl[6]: C12N-15/29, 15/82 A01H-5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
WPAT, CA

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
MEDLINE, DNA DATABASES (GENBANK, EMBL, SWISSPROT, PIR) see below

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
DNA DATABASES: SEQ ID Nos 4, 6, 8, 9 WPAT: [(C12N-015/29/IC OR A01H/IC) OR C12N-015/11/IC) AND (GENERATIVE OR GAMET: OR SPERM#)] OR (C12N-015/11/IC AND POLLEN:) MEDLINE: POLLEN/CT AND (GAMET? OR GERM? OR GENERATIVE OR SPERM?)
CA: POLLEN/CT AND [GENERATIVE OR SPERM OR (MALE GAMET?) OR (MALE(5N)GERMLINE)]

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	The Plant Journal 13(6), pages 823-829 (1998) Xu, Huiling et al "Plant homologue of human excision repair gene ERCCI points to conservation of DNA repair mechanism".	1-3
X	Plant Mol. Biol. 31 pages 1083-6 (1996) Blomstedt, C.K. et al "Generative cells of Lilium longiflorum possess translatable mRNA and functional protein synthesis machinery" See page 1084 column 1, line 14-completion of article	1-3

[X] Further documents are listed in the continuation of Box C

[ ] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
	28 AUG 1998
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929	Authorized officer **JIM CHAN** Telephone No.: (02) 6283 2340

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 98/00587

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Developmental Biology 169, pages 210-17 (1995) Ueda, K and Tanaka, I. "The Appearance of Male gamete-specific histones gH2B and gH3 during pollen development in Lilium longiflorum" See results and discussion	1-8
X	Planta 197, pages 289-92 (1995) Ueda, K. and Tanaka, I. "Male gametic nucleus-specific H2B and H3 histones designated gH2B and gH3, in Lilium longiflorum" See discussion	1-8
A	"Molecular and Cellular Aspects of Plant Reproduction", pages 83-135 (1994) Cambridge University Press. Scott, R.J. and Stead, A.D. eds. "The diversity and regulation of gene expression in the pathway of male gametophyte development" See in particular pages 106-107	1-10